It's a piece of growth hormone that does one thing — burn fat — without the blood sugar problems, IGF-1 elevation, or anabolic effects of full HGH. Here's the plain-English version.
Research context only. AOD-9604 is not FDA-approved for any indication. This page is for educational purposes based on published data. Not medical advice.
AOD-9604 stands for "Anti-Obesity Drug 9604." It's a synthetic fragment of human growth hormone — specifically amino acids 176–191 from the C-terminus of HGH. Researchers at Monash University in Australia isolated this fragment after discovering it was responsible for HGH's fat-burning effects while being separate from the growth-promoting effects.
The key insight: HGH does two major things — it promotes growth (via IGF-1) and it burns fat (via a different mechanism). AOD-9604 is just the fat-burning part, stripped of the growth promotion. That means no IGF-1 elevation, no effect on blood glucose, no anabolic activity — just targeted lipolysis.
The one-line version: AOD-9604 is a piece of growth hormone that was designed to do one job — stimulate fat burning — without any of the downsides that come with injecting full HGH.
It reached Phase 2 human clinical trials for obesity, which puts it a step above many research peptides that never leave animal studies. The trials showed meaningful fat loss results, though the compound never proceeded to Phase 3 for regulatory reasons unrelated to safety.
AOD-9604 binds to fat cells the same way the C-terminal region of HGH does — activating fat breakdown (lipolysis) and inhibiting new fat creation (lipogenesis).
Research suggests AOD-9604 works partly through beta-3 adrenergic receptors in fat tissue — the same receptors activated by exercise-induced adrenaline. This triggers fat cells to release stored fatty acids for fuel.
Unlike full HGH, AOD-9604 does not bind the GH receptor in a way that triggers IGF-1 production. This is why it has no effect on blood glucose, no anabolic muscle-building activity, and no impact on bone growth.
Emerging research suggests AOD-9604 may have beneficial effects on cartilage and joint tissue — potentially a secondary use case beyond fat metabolism. This is less well-established than its lipolytic effects.
Why this matters: Full HGH raises IGF-1, which raises blood glucose, can promote tumor growth, and causes insulin resistance at higher doses. AOD-9604's selective mechanism avoids all of that. It's the targeted scalpel vs HGH's sledgehammer.
Monash University ran multiple animal studies showing dose-dependent fat loss, followed by Phase 1 and Phase 2 human safety trials. The Phase 2 data showed fat mass reduction versus placebo in obese subjects, with a clean safety profile — no adverse metabolic effects, no abnormal lab findings, and no serious adverse events.
The compound didn't proceed to Phase 3 because the sponsoring company (Metabolic Pharmaceuticals) went through a restructuring, not because of safety or efficacy concerns. This is an important nuance — the clinical program stopped for business reasons, not scientific ones.
Evidence caveat: Phase 2 data is meaningful but not definitive. No large-scale Phase 3 trials exist. The fat loss results in trials were real but modest compared to GLP-1 class drugs. AOD-9604 is best understood as a targeted lipolysis tool, not a standalone weight loss drug.
AOD-9604 has one of the cleaner safety profiles in the research peptide space, which is a direct result of its selective mechanism. Since it doesn't interact with the IGF-1 pathway or affect blood glucose, the most common side effects associated with full HGH simply don't apply.
Notably absent from trial data: no joint pain, no carpal tunnel, no insulin resistance, no fluid retention — the classic HGH side effect profile. The Phase 2 safety data was clean enough that the FDA granted AOD-9604 GRAS (Generally Recognized As Safe) status as a food ingredient.
The GRAS designation: AOD-9604 is one of the few research peptides with FDA GRAS status, granted in 2014. This applies to its use as a food supplement ingredient, not as an injectable drug — but it signals the compound's favorable safety assessment at the regulatory level.
It's a fragment of HGH, not a diluted version. It shares the fat-metabolism portion of HGH's sequence but lacks the growth-promoting domain entirely. The two compounds have fundamentally different activity profiles — AOD-9604 won't raise IGF-1 no matter how high the dose.
No anabolic activity has been demonstrated for AOD-9604. It doesn't bind GH receptors in a way that drives protein synthesis or IGF-1. If you're looking for muscle-building effects, you're looking at the wrong peptide — this one is strictly a fat metabolism tool.
The clinical program stopped due to a company restructuring, not because trials showed the drug didn't work. Phase 2 showed positive results. The absence of Phase 3 data means we lack definitive large-scale proof — it doesn't mean the Phase 2 signal was wrong.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator